Evidence map›Paper›PMID 37012431›Full record

ArticleScientific reports2023

Rewiring of the 3D genome during acquisition of carboplatin resistance in a triple-negative breast cancer patient-derived xenograft.

Mikhail G Dozmorov, Maggie A Marshall, Narmeen S Rashid, Jacqueline M Grible, Aaron Valentine, Amy L Olex, Kavita Murthy, Abhijit Chakraborty, Joaquin Reyna, Daniela Salgado Figueroa and 6 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Therapeutic synergies that overcome carboplatin resistance in triple-negative breast cancer.Journal of experimental & clinical cancer research : CR · 2026
    Article
  4. Review
  5. Rewiring cancer: 3D genome determinants of cancer hallmarks.Current opinion in genetics & development · 2025
    Review
  6. Review
  7. Machine and Deep Learning Methods for Predicting 3D Genome Organization.Methods in molecular biology (Clifton, N.J.) · 2025
    Review
  8. Patient-Derived Xenografts of Breast Cancer.Advances in experimental medicine and biology · 2025
    Review
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Mikhail G Dozmorov *Department of Biostatistics, Virginia Commonwealth University, Richmond, VA, 23298, USA. Mikhail.Dozmorov@vcuhealth.org.
Maggie A Marshall *Department of Biostatistics, Virginia Commonwealth University, Richmond, VA, 23298, USA.
Narmeen S RashidDepartment of Pathology, Virginia Commonwealth University, Richmond, VA, 23284, USA.
Jacqueline M GribleDepartment of Pathology, Virginia Commonwealth University, Richmond, VA, 23284, USA.
Aaron ValentineDepartment of Pathology, Virginia Commonwealth University, Richmond, VA, 23284, USA.
Amy L OlexC. Kenneth and Dianne Wright Center for Clinical and Translational Research, Virginia Commonwealth University, Richmond, VA, 23298, USA.
Kavita MurthyCenter for Cancer Immunotherapy and Autoimmunity, La Jolla Institute for Immunology, La Jolla, CA, 92037, USA.
Abhijit ChakrabortyCenter for Cancer Immunotherapy and Autoimmunity, La Jolla Institute for Immunology, La Jolla, CA, 92037, USA.
Joaquin ReynaCenter for Cancer Immunotherapy and Autoimmunity, La Jolla Institute for Immunology, La Jolla, CA, 92037, USA.
Daniela Salgado FigueroaCenter for Cancer Immunotherapy and Autoimmunity, La Jolla Institute for Immunology, La Jolla, CA, 92037, USA.
Laura Hinojosa-GonzalezCenter for Cancer Immunotherapy and Autoimmunity, La Jolla Institute for Immunology, La Jolla, CA, 92037, USA.
Erika Da-Inn LeeDepartment of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, WI, 53792, USA.
Brittany A BaurDepartment of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, WI, 53792, USA.
Sushmita RoyWisconsin Institute for Discovery, University of Wisconsin-Madison, Madison, WI, 53715, USA.
Ferhat AyCenter for Cancer Immunotherapy and Autoimmunity, La Jolla Institute for Immunology, La Jolla, CA, 92037, USA.
J Chuck HarrellDepartment of Pathology, Virginia Commonwealth University, Richmond, VA, 23284, USA. Joshua.Harrell@vcuhealth.org.
Virginia Commonwealth University · USLa Jolla Institute for Immunology · USUniversity of Wisconsin–Madison · USWisconsin Institutes for Discovery · US

Funding

Virus Vector Shared ResourceP30CA016059 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Kim Felder Rhoads · 1985 to 2026
$51.0M
Research Supplement to Promote Diversity in Health Related ResearchUL1TR002649 · NCATS · VIRGINIA COMMONWEALTH UNIVERSITY · PI MOELLER, FREDERICK GERARD · 2018 to 2022
$19.1M
Studying the function of human genetic variation in the light of 3D genome organizationR35GM128938 · NIGMS · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI Ferhat Ay · 2018 to 2026
$4.6M
Circumventing acquired carboplatin resistance in triple-negative breast cancersR01CA246182 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI HARRELL, JOSHUA (CHUCK) · 2020 to 2024
$1.9M
Computational approaches for comparative regulatory genomics to decipher long-range gene regulationR01HG010045 · NHGRI · UNIVERSITY OF WISCONSIN-MADISON · PI ROY, SUSHMITA · 2018 to 2021
$1.4M
NCATS NIH HHS UL1 TR002649NCI NIH HHS P30 CA016059NCI NIH HHS R01 CA246182NHGRI NIH HHS R01 HG010045NIGMS NIH HHS R35 GM128938
6 · The paper itself

Abstract

Changes in the three-dimensional (3D) structure of the genome are an emerging hallmark of cancer. Cancer-associated copy number variants and single nucleotide polymorphisms promote rewiring of chromatin loops, disruption of topologically associating domains (TADs), active/inactive chromatin state switching, leading to oncogene expression and silencing of tumor suppressors. However, little is known about 3D changes during cancer progression to a chemotherapy-resistant state. We integrated chromatin conformation capture (Hi-C), RNA-seq, and whole-genome sequencing obtained from triple-negative breast cancer patient-derived xenograft primary tumors (UCD52) and carboplatin-resistant samples and found increased short-range (< 2 Mb) interactions, chromatin looping, formation of TAD, chromatin state switching into a more active state, and amplification of ATP-binding cassette transporters. Transcriptome changes suggested the role of long-noncoding RNAs in carboplatin resistance. Rewiring of the 3D genome was associated with TP53, TP63, BATF, FOS-JUN family of transcription factors and led to activation of aggressiveness-, metastasis- and other cancer-related pathways. Integrative analysis highlighted increased ribosome biogenesis and oxidative phosphorylation, suggesting the role of mitochondrial energy metabolism. Our results suggest that 3D genome remodeling may be a key mechanism underlying carboplatin resistance.

Indexed as

Triple Negative Breast NeoplasmsCarboplatinChromatinGenomeHeterograftsHumansCarboplatinChromatin

Identifiers

PMID37012431
PMCPMC10070455
OpenAlexW4362521111

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.